EvaluatePharma World Preview 2016, Outlook to 2022

Worldwide Rx Sales Forecast to Grow 6.3% p.a. to 2022

The ninth edition of the EvaluatePharma World Preview 2016, Outlook to 2022 report brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2022.

New this year - Worldwide Pharma Innovation 2008-2022 including insights into the companies with most valuable pipelines based on NPV analysis.

Key highlights

  • Worldwide prescription drug sales predicted to grow 6.3% (CAGR) between 2016 and 2022.

  • $169 billion in additional prescription drug sales in 2022 to come from R&D projects.

  • Novartis and Roche to compete head-to-head for the title of worldwide prescription drug sales in 2022; Pfizer to challenge them following the Medivation acquisition.

  • Worldwide pharmaceutical R&D spend expected to grow by 2.8% (CAGR) to $182 billion in 2022.

  • Celgene and Shire forecast to record the fastest sales growth (CAGR) by 2022 with increases of 16% and 19%, respectively.

  • New drug approvals in 2015 reach a record 56 NMEs, topping 2014’s record of 50

  • Oncology remains the largest therapy area in sales with a 12.5% (CAGR) growth rate from 2016 to 2022.

View EvaluatePharma World Preview 2016, Outlook to 2022 Executive Summary


Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.